Check this out: treatment paradigms in immune-checkpoint inhibitor colitis. Issue 1 (3rd January 2023)

• Record Type: Journal Article
• Authors: Kiparizoska, Sara; Murphy, Megan E.; Mattar, Mark C.
• Is Part Of: Current opinion in gastroenterology. Volume 39:Issue 1(2023)
• Page Start: 43
• Page End: 49
• Publication Date: 2023-01-03
• Subjects: immune checkpoint inhibitors -- immune-checkpoint inhibitor colitis -- immune-related adverse events; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1097/MOG.0000000000000892
• Languages: English
• ISSNs: 0267-1379

Abstract

Abstract : Purpose of review: Immune checkpoint inhibitors (ICI) have become a pillar of cancer therapy for many people around the world. However, up to two-thirds of all patients undergoing ICI therapy will have immune-related adverse events (irAEs), including immune-checkpoint inhibitor colitis (ICIC). This review summarizes the most valuable and currently available information about the mechanism, diagnosis, and management of ICIC. Recent findings: Recent findings include several developments on the leading theories for the mechanisms of ICIC such as the role of the gut microbiome. New emerging therapy strategies include tocilizumab, ustekinumab, mycophenolate mofetil, and calcineurin inhibitors. Summary: The occurrence of irAEs remains a limiting factor for the use of immunotherapy in cancer treatment. Prompt diagnosis of ICIC with endoscopy and histologic confirmation can lead to early utilization of known effective treatments such as corticosteroids, infliximab, vedolizumab, and other emerging therapy strategies. We summarize the key points of this review article in our abstract video, Supplemental Digital Content 1, http://links.lww.com/COG/A44 .